In dulaglutide trial simulations, adaptive design identified correct doses 88% of the time versus as low as 6% with fixed-dose design.
In plain wordsIn computer simulations, adaptive dulaglutide trial design selected correct doses more often than fixed-dose design.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- IncreaseCorrect dose selection
- Study
n: not reported in source
adaptive trial simulations- Comparator
- fixed-dose design
- Outcome group
- Overall treatment effect · Pharmacology
Measurements
- Correct dose selection
- 88%
- adaptive design
- Correct dose selection
- 6%
- fixed-dose design, as low as
Source sentences
Simulations demonstrated that the adaptive design would identify the correct doses 88% of the time, compared to as low as 6% for a fixed-dose design (the latter value based on frequentist decision rules analogous to the Bayesian decision rules for adaptive design).
1 context sentence(design, population, supporting numbers)
The operating characteristics of the trial were assessed by extensive simulation studies.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).